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Abstract
Growth factor signaling pathways are tightly regulated by phosphorylation and include many important kinase targets of
interest for drug discovery. Small molecule inhibitors of the bone morphogenetic protein (BMP) receptor kinase ALK2
(ACVR1) are needed urgently to treat the progressively debilitating musculoskeletal disease fibrodysplasia ossificans
progressiva (FOP). Dorsomorphin analogues, first identified in zebrafish, remain the only BMP inhibitor chemotype reported
to date. By screening an assay panel of 250 recombinant human kinases we identified a highly selective 2-aminopyridine-
based inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current lead
compound LDN-193189. K02288 specifically inhibited the BMP-induced Smad pathway without affecting TGF-b signaling
and induced dorsalization of zebrafish embryos. Comparison of the crystal structures of ALK2 with K02288 and LDN-193189
revealed additional contacts in the K02288 complex affording improved shape complementarity and identified the exposed
phenol group for further optimization of pharmacokinetics. The discovery of a new chemical series provides an independent
pharmacological tool to investigate BMP signaling and offers multiple opportunities for pre-clinical development.
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Introduction
Members of the transforming growth factor-beta (TGF-b)
superfamily bind transmembrane receptor serine/threonine kinas-
es to activate Smad and non-Smad pathways for the control of
normal development and tissue repair [1,2]. Ligand binding
induces type II receptor phosphorylation of associated type I
receptors, leading to Smad recruitment and phosphorylation by
the type I receptor [3,4]. The receptor-associated Smads (R-
Smads) subsequently assemble with co-Smad4 for nuclear
transport and transcriptional activation [5].
Small molecule inhibitors of the type I receptors (also known as
activin receptor-like kinases, ALK1-7) have proved to be valuable
pharmacological tools to characterize TGF-b and BMP pathways
in signaling, as well as stem cell biology [6,7]. TGF-b inhibitors
such as SB-431542 inhibit Smad2/3 phosphorylation by ALK4,
ALK5 and ALK7, as well as non-classical Smad1/5 phosphory-
lation by ALK5 [8]. Conversely, inhibitors of BMP signaling have
recently been described that specifically inhibit Smad1/5/8
phosphorylation by ALK1, ALK2, ALK3 and ALK6 [9,10,11].
Notably, these molecules have shown efficacy in a variety of
disease models, including chronic anemia [12,13,14], prostate
cancer [15], muscle wasting [16], heterotopic ossification [17],
atherosclerosis and vascular calcification [18,19].
While specific TGF-b inhibitors have been developed over
many years [20], BMP inhibitor development remains at an early
stage [6]. New leads in this target area are desirable for several
reasons. First, current work follows a single high throughput screen
performed in the zebrafish system [9]. Second, independent tool
compounds are preferred for functional validation, whereas the
screening hit dorsomorphin [9], and derivatives DMH1 [10] and
LDN-193189 [11,17], share the same pyrazolo[1,5-a]pyrimidine
scaffold. Third, more selective compounds are needed to minimize
unwanted off-target effects [7].
Most importantly, there is an urgent need for selective ALK2
inhibitors to treat the debilitating bone disorder fibrodysplasia
ossificans progressiva (FOP) [21]. FOP sufferers carry a gain of
function mutation in the intracellular domain of ALK2,
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connective tissue that ultimately renders movement impossible
[22]. Trauma and surgery only accelerate the condition, while
biological inhibitors lacking cell penetrance are ineffective [23].
As an alternative but complementary strategy to phenotypic
screens, we used direct screening of recombinant human kinases to
identify new inhibitor leads against ALK2. We report a novel
BMP inhibitor scaffold, comprising a 2-aminopyridine core and a
trimethoxyphenyl specificity group, which is both potent and
selective. The identified inhibitor K02288 provides a new
pharmacological tool to investigate the diversity of BMP signaling
in both normal and pathobiology.
Results
Identification of a Novel 2-aminopyridine Inhibitor of
ALK2
To identify new potent and selective inhibitors of ALK2 we
screened a kinase-directed library of 2000 compounds, including
known biologically active molecules as well as novel chemo-
types, against a panel of 80 purified human kinases using
differential scanning fluorimetry (DSF) in a 96-well plate format
[24,25]. In this fluorescence-based thermal shift assay, com-
pound binding to the native protein is observed as a relative
increase in the protein’s melting temperature (Tm shift),
proportional to the binding affinity. Typically for a protein
kinase in the presence of 10 mM compound a Tm shift of 4uC
corresponds to KD of 1 mM, whereas a Tm shift above 8uC
reflects a KD of 100 nM or less [26].
Screening of human ALK2 was performed on the kinase
domain residues 201–499 including the activating mutation
Q207D. The known screening hit dorsomorphin produced a
reference Tm shift of 10.3uC, consistent with its reported in vitro
IC50 of 50 nM [6] (Figure 1A). A novel hit compound K02288 (3-
[6-amino-5-(3,4,5-trimethoxy-phenyl)-pyridin-3-yl]-phenol) was
identified containing a 2-aminopyridine scaffold that produced a
significantly higher Tm shift of 13.1uC, suggestive of an improved
affinity (Figure 1A). In the screen, a similarly high Tm shift
(14.3uC) was observed only for the optimized dorsomorphin
derivative LDN-193189 (Figure 1A). Importantly, K02288 was
highly selective against the screening panel, showing a Tm shift
greater than 8uC only for the homologous kinases ALK1-6 and
ActRIIA (supplemental Table S1; values were again intermediate
to those of dorsomorphin and LDN-193189). The screen also
confirmed the binding of LDN-193189 to AMPKa2, as well as the
more promiscuous binding of dorsomorphin (supplemental Table
S1).
To confirm K02288 as a direct inhibitor of the activin receptor-
like kinases we compared the activity of this hit compound against
that of LDN-193189 in an in vitro kinase assay (Figures 1B and
1D). K02288 and LDN-193189 were most potent against the type
I BMP receptors ALK1 and ALK2 (IC50s in the 1–2 nM range),
which share 79% sequence identity within their kinase domains.
Inhibition of other type I BMP receptors was slightly weaker
(ALK3 and ALK6, IC50s of 5–34 nM). Both inhibitors also
displayed an approximately 300-fold selectivity for ALK2 over the
TGF-b receptor ALK5 (K02288 IC50=321 nM). Interestingly,
K02288 further demonstrated an improved selectivity against
ALK4 (IC50=302 nM). Finally, some weak inhibition of the type
II BMP receptor ActRIIA was confirmed for both compounds,
consistent with the thermal shift assay (IC50s of 210–220 nM,
Figures 1C and 1D).
Kinome-wide Selectivity
Enzymatic screening was extended to a further panel of 200
human kinases to evaluate the kinome-wide selectivity of K02288
and LDN-193189. Percentage inhibition was determined for each
kinase at both 0.1 mM and 1 mM inhibitor concentration
(supplemental Table S2). Overall, the selectivity profile of
K02288 was more favorable than LDN-193189 (Figure 2A).
K02288 showed .50% inhibition against only ABL and ARG
(ABL2) at 0.1 mM inhibitor concentration, and only a further 6
kinases at 1 mM. In comparison, 1 mM LDN-193189 showed
.50% inhibition against 21 kinases (10%), although only ABL and
SIK2 were similarly inhibited at 0.1 mM. We were also interested
to examine the extent to which the activities of K02288 and LDN-
193189 were overlapping and thus the novelty of the K02288
chemical probe. We therefore plotted the percentage kinase
inhibition values determined with 1 mM K02288 against those for
1 mM LDN-193189 to check for any correlation. As shown in
Figure 2B, relatively few kinases, like ABL, were observed close to
the diagonal, where activities are equivalent, indicating that the
divergent inhibitor scaffolds yielded distinct selectivity profiles.
Strikingly, a number of kinases, including KDR (VEGFR2), were
inhibited exclusively by LDN-193189, but not by K02288
(Figure 2B). When visualized on a kinase phylogenetic tree, these
were primarily clustered within the receptor tyrosine kinases (TKs)
as well as the calmodulin-dependent kinases (CAMKs) (Figure 2C).
Structural Basis for Inhibitor Binding
To define the mode of action of K02288 we determined its
structure in complex with the kinase domain of ALK2 refined at
2.15 A ˚ resolution (Figure 3A). The entire chain was traced from
residues 202–499, including parts of the L45 loop and activation
loop (A-loop) that were previously disordered in the structure of
the ALK2-FKBP12 complex [27] (data collection and refinement
statistics are provided in Table 1). Interestingly, the structure of the
kinase domain was essentially unchanged by the loss of the GS
domain, demonstrating that its inactive conformation was
relatively stable (supplemental Figure S1). In particular, the ATP
pocket remained occluded by the inhibitory conformations of the
A-loop and aC helix, which were stabilized by the hydrogen bond
interactions of R375 (A-loop) with S244 (aC), D336 (catalytic loop
HRD motif) and D354 (A-loop DLG motif).
The 2-aminopyridine of K02288 was bound to the kinase hinge
region in an ATP-mimetic fashion with two hydrogen bonds to
H284 and H286, respectively (Figure 3A). The large trimethox-
yphenyl substituent occupied the central pocket area sandwiched
between the hydrophobic residues V222, L263, L343 and A353.
Two of the three methoxy groups additionally formed a water-
mediated hydrogen bond to the catalytic lysine (K235). The
solvent channel was occupied by the phenol group, which formed
an additional hydrogen bond with D293 (Figure 3A). The high
affinity interaction of the inhibitor was confirmed by isothermal
titration calorimetry (ITC), which indicated a KD of 7.9 nM, close
to the limit of measurement (Figure 3B).
We subsequently solved the ALK2 co-structure with LDN-
193189 refined at 1.8 A ˚ to compare its interaction (Figure 3C).
The pyrazolo[1,5-a]pyrimidine core was bound similarly to the
parent molecule dorsomorphin [27] with a single hydrogen bond
to the hinge. Replacement of the 4-pyridine ring with 4-quinoline
conserved the water-mediated hydrogen bond to E248 (aC helix),
whilst providing improved potency through increased hydropho-
bic interaction. The piperazine substituent, selected for metabolic
stability [11], was exposed to solvent. Superposition of the K02288
and LDN-193189 co-structures revealed a slight difference in their
hinge-binding orientations allowing the trimethoxyphenyl of
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Notably, the three methoxy substituents were able to extend more
deeply towards the recesses of the pocket periphery, potentially
contributing to the high selectivity of K02288. Indeed, the
exquisite shape complementarity of this inhibitor scaffold was
revealed by a ligand spacefill model and a surface skin
representation of ALK2 (Figure 3D).
K02288 Selectively Inhibits the BMP-Smad Pathway
The potent and selective activity of K02288 against ALK2 and
related BMP receptors led us to explore the potential utility of
K02288 as a chemical probe for BMP signaling in cells. The cell
penetrance and activity of the compound were first confirmed
using C2C12 cells and the ligand BMP4. Stimulation with BMP4
led to a robust phosphorylation of Smad1/5/8 that was reduced
by K02288 in a dose dependent manner with an apparent IC50 of
100 nM (Figure 4A). Similar results were observed using a BMP
response element (BRE)-luciferase reporter assay (Figure 4B). In
both assays, the K02288 activity was 10-fold weaker than the
control compound LDN-193189 (IC50=10 nM), suggesting that
the K02288 scaffold should be optimized further for its cellular
and metabolic stability.
Figure 1. Identification of a novel 2-aminopyridine inhibitor of ALK2. (A) Schematic summary of a thermal shift assay screen using
recombinant ALK2 kinase domain. A novel 2-aminopyridine hit K02288 was identified with an affinity for ALK2 intermediate between dorsomorphin
and LDN-193189. Complete screening data are shown in supplemental Table S1. (B) In vitro kinase assays showed K02288 specificity for ALK1,2,3,6
over ALK4,5. IC50 measurements were performed in triplicate at the Km value of ATP. (C) ActRIIA kinase inhibition was determined using the Kinase-
GloH assay (Promega). IC50 measurements were performed in duplicate at the Km value of ATP. (D) Summary of IC50 measurements in all experiments.
doi:10.1371/journal.pone.0062721.g001
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ligands in the TGF-b superfamily to corroborate their specificity
(Figure 4C). Indeed, the specificity of K02288 and LDN-193189
was remarkably similar, consistent with the thermal shift and
in vitro kinase assay data. As expected, both compounds exhibited
the highest activity against BMP6, a preferred ligand for ALK2
[28], with 50 nM K02288 giving near complete inhibition of
Smad1/5/8 phosphorylation (Figure 4C). Neither compound
inhibited TGF-b–induced phosphorylation of Smad2, in agree-
ment with their observed specificity for ALK2 over ALK5
(Figure 4C). Activin A–induced phosphorylation of Smad2 was
not observed in C2C12 cells and was tested instead in HEK293
cells. Interestingly, both compounds showed some weaker
inhibition of this pathway, with near complete inhibition of
Smad2 phosphorylation by 0.5 mM K02288 or LDN-193189
(Figure 4C). This activity likely reflects some weak inhibition of
ALK4 or the type II activin receptors.
K02288 Induces Dorsalization of Zebrafish Embryos
To further validate K02288 as a pharmacological tool we tested
its effects on Tg(BRE:mRFP) transgenic zebrafish embryos, which
expressed monomeric red fluorescent protein (mRFP) under the
control of a BMP response element [29]. Intact BMP signaling has
been shown to be essential for proper specification of tissue
progenitors across the dorsoventral axis [30]. Treatment with
K02288 induced a dorsalized phenotype in a dose dependent
manner (Figure 5A), as shown previously for dorsomorphin [9]. A
severely dorsalized phenotype was observed at 8–10 mM concen-
tration (Figure 5B) correlating with the loss of expression of mRFP
protein (Figure 5C).
Finally, at 12 hours post fertilization (hpf) different inhibitors
were administered to Tg(fli1a:eGFP) zebrafish embryos to compare
their off-target effects on vascular development (Figure 6). At
48 hpf, embryos treated with 10 mM dorsomorphin or LDN-
193189 exhibited defects in intersomitic vessel (ISV) formation,
consistent with their known inhibition of VEGF signaling
(reported KDR IC50s of 25 nM and 215 nM, respectively [10]).
In contrast, no ISV defects were observed using 10–20 mM
K02288 (Figure 6 and data not shown), as predicted by the
screening data showing no inhibition of KDR (supplemental Table
S2).
Discussion
The development of selective small molecule inhibitors of
protein kinases presents a major challenge due to the high
sequence conservation of the ATP pocket. Here we report a novel
2-aminopyridine inhibitor K02288 with potent and selective
activity against type I BMP receptor kinases. The 2-aminopyridine
group is an ATP-mimetic that binds the kinase hinge region
Figure 2. Kinome-wide selectivity of K02288 and LDN-193189. (A) Some 200 human kinases were individually ranked according to their
enzymatic inhibition by K02288 or LDN-193189 present at 0.1 or 1 mM concentration (screening performed by Nanosyn). Complete screening data are
shown in supplemental Table S2. (B) Percent inhibition values for each kinase in the presence of 1 mM K02288 were plotted against those using 1 mM
LDN-193189. There is little correlation between those kinases inhibited by K02288 and by LDN-193189. Overall, fewer kinases were inhibited by
K02288. (C) Kinome tree visualization of inhibitor profiling showing the appearance of target family clusters (illustration reproduced courtesy of Cell
Signaling Technology, Inc.; www.cellsignal.com).
doi:10.1371/journal.pone.0062721.g002
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kinase inhibitors with this scaffold have been identified previously
[31,32]. The most advanced molecule crizotinib, which targets the
receptor tyrosine kinases ALK and c-MET, has been approved by
the US Food and Drug Administration for the treatment of
patients with ELM4-ALK positive non-small-cell lung carcinoma
[33]. Moreover, 3,5-diaryl-2-aminopyridines resembling K02288
were recently discovered as anti-malarials [34] (Figure 7), although
we observed no effect of the lead compound on BMP or TGF-b
signaling (data not shown).
K02288 exhibits remarkable potency for a low molecular weight
screening hit, both in enzymatic assays (IC50s in the range 1–2 nM
against ALK1 and ALK2) and in C2C12 cells (IC50,50 nM
against BMP6 signaling). In comparison, the one previous
screening hit dorsomorphin displayed IC50so f5 0 n Mi n
enzymatic assays [6] and ,0.5 mM in C2C12 cells [35]. These
activities were improved significantly following further chemistry
to yield the lead derivative LDN-193189 [11,17]. Similar
optimization of the cellular and in vivo activity of K02288 would
be beneficial to fully exploit its significant selectivity and could be
achieved by replacement of the potentially vulnerable phenol
moiety. In the crystal structure of the ALK2-K02288 complex this
group bound to the exposed solvent channel where substitutions
are likely to be well tolerated.
The discovery of diverse BMP inhibitor scaffolds establishes a
repertoire of pharmacological tool compounds for cross-validation
in investigations of cellular signaling. Moreover, the application of
multiple orthogonal chemotypes may help to discern whether a
particular toxicological liability is a class-wide pharmacological
phenomenon due to ALK2 inhibition or the result of a chemotype
specific off-target effect. The novel inhibitor K02288 provides an
exciting new starting point for further chemistry with potential
therapeutic applications in stem cell engineering, as well as in
disease models of anemia, musculoskeletal dysplasia and cancer.
Materials and Methods
Protein Expression and Purification
The human ALK2 kinase domain, residues 201–499 includ-
ing the activating mutation Q207D, was subcloned into the
vector pFB-LIC-Bse. Baculoviral expression was performed in
Sf9 insect cells at 27uC, shaking at 110 rpm. Cells were
harvested at 48 hours post infection and resuspended in 50 mM
HEPES pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol,
0.1 mM TCEP, supplemented with protease inhibitor set V
(Calbiochem). Cells were lysed using a C5 high pressure
homogenizer (Emulsiflex) and the insoluble material excluded
by centrifugation at 21,000 rpm. Nucleic acids were removed
on a DEAE-cellulose column before purification of the N-
Figure 3. Structural basis for inhibitor binding to ALK2. (A) Structure of the ALK2-K02288 complex. Inset shows the interactions of K02288 in
the ATP pocket. Hydrogen bonds are shown as dotted lines. (B) ITC measurements showed ALK2 bound K02288 with KD=7.9 nM. (C) Comparison of
the binding modes of K02288 (green) and LDN-193189 (yellow) in ALK2. Both inhibitors formed hydrogen bonds to the hinge residue H286, but other
interactions were divergent, including water-mediated hydrogen bonds to K235 and E248, respectively. (D) A spacefill representation of K02288
shown against a surface mesh view of the ATP pocket highlights the shape complementarity in ALK2.
doi:10.1371/journal.pone.0062721.g003
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raphy. The eluted protein was cleaved with TEV protease and
further purified by size exclusion chromatography using a S200
HiLoad 16/60 Superdex column. A final clean up step was
performed by reverse purification on a Ni-sepharose column
and the buffer adjusted to 50 mM HEPES pH 7.5, 300 mM
NaCl, 10 mM DTT, 50 mM L-arginine and 50 mM L-
glutamate. Excess protein was flash frozen and stored at
280uC.
Differential Scanning Fluorimetry (DSF)
Thermal melting experiments were performed using a Real
Time PCR machine Mx3005p (Stratagene) with a protein
concentration of 1–2 mM and 10 mM inhibitor as described
previously [24,25]. A kinase-directed compound set, including
K02288, was purchased from Biofocus (DPI). Dorsomorphin and
other known biologically active kinase inhibitors were purchased
from Calbiochem. LDN-193189 was prepared as described
previously [11]. Recombinant human kinases for DSF screening
were prepared by SGC using published methods [26,36].
In vitro Kinase Assay for ALK1-6
Kinase reactions for ALK1-6 were performed at room
temperature for 45 minutes in 96-well plates mixing 2.5 nM
kinase (Invitrogen), 0.5 mg/mL dephosphorylated casein (Sigma),
6 mM ATP (Sigma), 0.05 mCi/mL[ c-
32P]ATP (Perkin Elmer),
10 mM MnCl2 and 0.2% BSA in kinase buffer (Cell Signaling).
Inhibitors were added at concentrations between 0 and 10 mMi n
kinase reaction buffer and tested in triplicate. Reactions were
quenched with phosphoric acid, bound to 96-well P81 phospho-
cellulose filter plates (Millipore) and assayed with Microscint 20
scintillation fluid (Perkin Elmer) using a Spectramax L luminom-
eter (Molecular Devices). Data were normalized to untreated
controls at 100% enzyme activity and negative controls subtracted
as background. IC50 values were calculated using GraphPad
(Prism software).
Kinase-GloH Assay
A kinase assay for ActRIIA (ACVR2) was performed using
Kinase-GloH (Promega) as per manufacturer’s instructions. Briefly,
the following were mixed and reacted at room temperature for 3
hours in a 96-well plate at a final volume of 100 mL, 10 nM kinase
(,EC50 at 2 hr), 0.5 mg/mL dephosphorylated casein (Sigma),
10 mM ATP (Promega), 10 mM MnCl2 and 0.2% BSA in kinase
buffer (Cell Signaling). Inhibitors were added at concentrations
between 0 and 10 mM in kinase reaction buffer and tested in
duplicate. At 15 min, 30 min, 1 hr, 2 hr, and 3 hr 20 mL aliquots
of the reaction mixture was transferred to a 384-well plate and
20 mL of Kinase-GloH was added and allowed to rest for 10 min to
quench the reaction and produce light which was measured using
a Spectramax L luminometer (Molecular Devices). The 2 hr time
point was within the linear portion of the reaction and was used for
calculations due to favourable signal-to-noise ratio and was
consistent with earlier time points. Data were normalized to
Table 1. Diffraction data and refinement statistics.
PDB accession code 3MTF 3Q4U
Data collection
Beamline Diamond I04 Diamond IO3
Wavelength (A ˚) 0.9762 0.9763
Resolution
a (A ˚) 41.8522.15 (2.2722.15) 41.8821.82 (1.9221.82)
Spacegroup P 21 21 2 P 21
Cell dimensions a=83.7, b=138.3, c=59.9 A ˚ a=83.6, b=98.7, c=83.9 A ˚
a=b=c=90.0u a=c=90.0u; b=117.4u
No. unique reflections
a 37,445 (4,945) 107,198 (15,312)
Completeness
a (%) 97.3 (90.5) 99.2 (97.8)
I/sI
a 10.5 (2.9) 11.6 (2.0)
Rmerge
a (%) 15.5 (63.8) 8.6 (73.4)
Redundancy
a 7.9 (5.3) 4.3 (4.2)
Refinement
Ligands K02288 LDN-193189
No. refinement atoms (P/L/O)
b 4,724/52/497 9,767/124/1,243
Rfact (%) 18.2 16.3
Rfree (%) 24.4 21.9
Bf (P/L/O)
b (A ˚2) 25/17/33 28/23/37
rms deviation bond
c (A ˚) 0.016 0.016
rms deviation angle
c (u) 1.6 1.6
Molprobity
Ramachandran favour 97.6% 97.8%
Ramachandran allowed 99.7% 100%
aValues in brackets show the statistics for the highest resolution shells.
bP/L/O indicate protein, ligand molecules presented in the active sites, and other (water and solvent molecules), respectively.
crms indicates root-mean-square.
doi:10.1371/journal.pone.0062721.t001
A New Small Molecule Inhibitor of BMP Signaling
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e62721untreated controls at 100% enzyme activity and negative controls
subtracted as background. IC50 values were calculated using
GraphPad Prism (GraphPad Software, Inc).
Kinase-wide Selectivity Profiling
Inhibitor selectivity profiling against 200 human kinases at 0.1
and 1 mM inhibitor concentration was performed by Nanosyn
(www.nanosyn.com).
Crystallization, Data Collection and Structure
Determination
Crystallization was performed using the sitting drop vapour
diffusion method at 20uC. Viable crystals of ALK2 in complex
with LDN-193189 grew in a 150 nL drop mixing 10 mg/mL
protein, pre-incubated with 1 mM compound, with a reservoir
solution containing 20% PEG3350, 0.2 M ammonium citrate
dibasic pH 5.0 at 1:1 volume ratio. Crystals were transferred into a
cryo-protective solution prepared from the mother liquor supple-
mented with 20% ethylene glycol. Diffraction data were collected
at Diamond Light Source, beamline I03. For the K02288
complex, frozen ALK2 protein was thawed, purified from
aggregates on a S200 HiLoad 16/60 Superdex column, and
concentrated to 7 mg/mL. Viable crystals of ALK2 in complex
with K02288 grew in a 150 nL drop mixing the protein, pre-
incubated with 1 mM compound, with a reservoir solution
containing 1.6 M Na/K phosphate, 0.1 M HEPES pH 7.5 at
1:2 volume ratio. Crystals were transferred into a cryo-protective
solution prepared from the mother liquor supplemented with 25%
ethylene glycol. Diffraction data were collected at Diamond Light
Source, beamline I04. Data were processed and scaled with
MOSFLM and SCALA from CCP4 suite [37,38]. Structures were
solved by molecular replacement using PHASER [39] and the
structure of ALK2 from the ALK2-FKBP12-dorsomorphin
complex [27] as a search model. Subsequent manual model
building was performed using COOT [40] alternated with
refinement in REFMAC [41]. TLS-restrained refinement was
applied in the latter cycles using the input thermal motion
parameters determined by the TLSMD server [42]. The final
models were verified for geometry correctness with MOLPROB-
ITY [43]. Data collection and refinement statistics are summa-
rized in Table 1.
Figure 4. K02288 selectively inhibits BMP signaling. (A) K02288 and LDN-193189 inhibited BMP4 induced Smad1/5/8 phosphorylation in
C2C12 cells. Phosphorylated Smads and total Smads were detected by Western blot. (B) BRE-luciferase assay in C2C12 cells showing the dose
dependent inhibition of the BMP4 response. Cells were treated with LDN-193198 or K02288 at the indicated concentrations prior to BMP4
stimulation. Y-axis displays the ratio of Firefly/Renilla activity from three independent experiments each performed in triplicate 6 S.E.M. (C) K02288
and LDN-193189 potently inhibited BMP6-induced Smad1/5/8 phosphorylation in C2C12 cells, but had no effect on TGF-b-induced phosphorylation
of Smad2. Activin A-induced P-Smad2 in HEK293 cells was weakly inhibited by K02288 and LDN-193189.
doi:10.1371/journal.pone.0062721.g004
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C2C12 and HEK293 cells were grown in DMEM supplement-
ed with 10% FCS (PAA) and seeded at a density of 1 x 10
5 cells
per well in 6-well plates. The next day the cells were starved in
DMEM containing 1% FCS for 5 hours. Inhibitors were added at
the indicated concentrations for 30 minutes followed by 10 ng/mL
BMP4 (Peprotech), 100 ng/mL BMP6 (Peprotech), 100 ng/mL
Activin A (Peprotech) or 2 ng/mL TGF-b1 (Cell Signaling) for 1
hour. Cells were washed in PBS and lysed on ice for 30 minutes in
lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton
X-100, 25 mM NaF, 25 mM Na b-glycerophosphate, 2 mM
Na3VO4) containing protease inhibitors (Roche). Protein concen-
tration in the clarified lysate was determined by Bradford Assay
(Pierce) and 15 mg run on 4–12% Bis-Tris gel (Biorad). The
protein was transferred onto nitrocellulose membrane (GE
Healthcare) and probed with the relevant antibody at 4uC
overnight (Cell Signaling: anti-Smad 1 (#9743), anti-P-Smad 1/
5/8 (#9511), anti-Smad 2 (#5339), anti-P-Smad 2 (#3101). After
subsequent incubation with HRP-conjugated anti-rabbit antibody,
protein bands were detected using ECL (Pierce) and an LAS4000
image reader. Cells were purchased originally from the European
Collection of Cell Cultures (ECACC) available through Sigma.
Dual Luciferase Reporter Assay
C2C12 cells were co-transfected using lipofectamine 2000 with
BRE-luciferase [44] and Renilla Luciferase pRLTK (Promega)
following the manufacturer’s instructions. 16 hours post transfec-
tion cells were starved in DMEM containing 1% FCS for 5 hours.
Inhibitors were added to triplicate wells at the indicated
concentrations for 30 minutes, followed by overnight stimulation
with 10 ng/ml BMP4 (Peprotech). Luciferase activities were
determined according to the Dual-LuciferaseH Reporter Assay
System (Promega) using Renilla for normalization of transfection
efficiency.
Fish Maintenance and Transgenic Lines
The zebrafish colony was maintained as described [45] and
embryos were raised at 28.5uC. The Tg(BRE:mRFP) transgenic
line (also called BRE-mRFP) has been described previously [29]
and expresses mRFP in response to BMP signaling. The
Tg(fli1a:eGFP) transgenic line has also been described and used
to test the off-target effects of dorsomorphin and LDN-193189 on
vasculature development [10,46,47].
Figure 5. K02288 induces dorsalization of zebrafish embryos. (A) Brightfield photographs of 26 hours old Tg(BRE:mRFP) transgenic embryos
treated with DMSO or varying doses of K02288 from the 8- to 16-cell stage. Severity of the dorsalization correlated with the dose of K02288. Very
strong dorsalized phenotypes were observed with 8–10 mM K02288. (B) The phenotypes of the embryos shown in A were classified according to
Kishimoto et al. [49]. (C) Western blot for mRFP in extracts prepared from Tg(BRE:mRFP) embryos treated in a parallel experiment. Loss of mRFP
protein was evident at 8–10 mM K02288. As a control, the effects of dorsomorphin (DM) and LDN-193189 (LDN) on mRFP expression are also shown.
Protein loading control is shown with the MCM6 blot.
doi:10.1371/journal.pone.0062721.g005
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Inhibitor stocks were diluted in DMSO and then further diluted
in fish water to give the required inhibitor concentrations. To
minimize the amount of inhibitors used, experiments were
performed in 24-well plates with approximately 20 embryos per
well in a volume of 1 mL. The chemical treatment was applied by
immersing 8- to 16-cell stage Tg(BRE:mRFP) embryos (dorsaliza-
tion experiment) or 12 hours old Tg(fli1a:eGFP) embryos (ISV
experiment) in the fish water supplemented with DMSO or the
chemical inhibitors. For the ISV experiment, embryos were
manually dechorionated after bud stage before treatment.
Embryos were scored and photographed at 26 or 48 hours.
Zebrafish Protein Extraction and Western Blotting
Ten non-dechorionated 26 hours old treated Tg(BRE:mRFP)
embryos were snap frozen on dry ice and stored at 280uC. Protein
extracts were prepared as described previously for Xenopus embryos
[48]. Extraction buffer was freshly prepared. 10 mL per embryo of
Figure 6. K02288 does not inhibit vasculature development. (Top panels) Brightfield photographs of 48 hours old Tg(fli1a:eGFP) embryos
treated with DMSO or chemical inhibitors from 12 hours post fertilization. Embryos were manually dechorionated after bud stage before treatment.
(Center panels) Same view under UV light for visualization of eGFP expression in the vasculature. Dorsomorphin and LDN-193189 treatment resulted
in intersomitic vessel (ISV) formation defects, consistent with their known inhibition of VEGF signaling. (Lower panels) Higher magnification views of
representative embryos and phenotype summary. The most severe phenotypes were observed with dorsomorphin. No effects on ISV formation were
observed with K02288 treatment.
doi:10.1371/journal.pone.0062721.g006
Figure 7. The K02288 scaffold is similar to an anti-malarial compound. (A) The 2-aminopyridine scaffold of K02288. (B) A similar initial hit 1
was identified in a recent anti-malarial screen and optimized to the more divergent lead 2 in development of the pre-clinical candidate MMV390048
[34].
doi:10.1371/journal.pone.0062721.g007
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plastic pestle and a pellet pestle motor (Kontes). 40 mg( , 1
embryo equivalent) of protein extract was loaded per lane on a
12.5% SDS-PAGE gel. The rabbit anti-mRFP (Invitrogen,
R10367) and the goat anti-MCM6 (Santa Cruz, sc-9843)
antibodies were used for Western blots.
Supporting Information
Figure S1 The ALK2 kinase domain adopts an inactive
conformation. Superposition of the ALK2-K02288 structure
(PDB 3MTF) and the ALK2-FKBP12-dorsomorphin structure
(PDB 3H9R) reveals no structural change despite the absence of
the GS domain and bound FKBP12. The kinase domain in ALK2
appears stable in an inactive conformation. In particular, the ATP
pocket is occluded by the inhibitory conformations of the
activation segment (including the b9-b10 hairpin) and the aC
helix, which are stabilized by the hydrogen bond interactions of
R375 (activation segment) with S244 (aC), D336 (catalytic loop
HRD motif) and D354 (activation segment DLG motif).
(TIF)
Table S1 Differential scanning fluorimetry screening
against 80 recombinant human kinases.
(PDF)
Table S2 Kinome-wide selectivity profiling performed
by Nanosyn (www.nanosyn.com).
(PDF)
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